Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18639804 | 0.88 | MAOB (0.55) | MAOBMAOACYP11B1CYP11B2NPC1 | |
| SCHEMBL188284 | 0.88 | MAOB (0.55) | MAOBMAOAAPPNPC1RAB9A | |
| SCHEMBL4435816 | 0.88 | MAOB (0.57) | MAOBMAOAAPPNPC1RAB9A | |
| SCHEMBL13739621 | 0.88 | APP (0.49) | MAOBMAOACYP11B1CYP11B2APP | |
| SCHEMBL20465388 | 0.85 | MAOB (0.76) | MAOBMAOACYP11B1CYP11B2APP | |
| SCHEMBL427002 | 0.85 | MAOB (0.74) | MAOBMAOACYP11B1CYP11B2 | |
| SCHEMBL12907083 | 0.83 | MAOB (0.47) | MAOBMAOACYP11B1CYP11B2 | |
| SCHEMBL4426825 | 0.83 | MAOB (0.52) | MAOBMAOACYP11B1CYP11B2 | |
| SCHEMBL8135327 | 0.82 | MAOB (0.54) | MAOBMAOACYP11B1CYP11B2 | |
| SCHEMBL2539990 | 0.82 | CYP11B1 (0.58) | MAOBCYP11B1CYP11B2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | MAOB 563/4885MAOA 2305/4885CYP11B1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.